infliximab

Home
Ligands
infliximab

GtoPdb Ligand ID: 5004

infliximab is an approved drug (FDA (1998), EMA (1999))

Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [5].

Biosimilars:

Name	Trade name	Company	Clinical Phase	Indications	References
infliximab-dyyb; CT-P13	Remsima; Inflectra; Flammegis	Celltrion/Pfizer	Approved (2013 EMA, 2016 FDA)	As per reference agent	[1-2,8]
infliximab-abda; SB2	Flixabi; Renflexis	Merck/SamsungBioepis	Approved (2016 EMA, 2017 FDA)	As per reference agent
infliximab-qbtx; PF-06438179	Ixifi; Zessly	Pfizer?Sandoz	Approved (2017 FDA, 2018 EMA)	As per reference agent	[3]
NI-071		Nichi-Iko Pharmaceutical	Approved (2017 Japan); Phase 3 US (NCT02990806)	As per reference agent
BCD-055		Biocad	Ph 3 (NCT02762838)	Rheumatoid arthritis
Infliximab-EPIRUS; BOW015	Infimab	Epirus Biopharmaceuticals	Approved (2014 India); Ph 3 US (NCT02683564)	Rheumatoid arthritis
infliximab-axxq; ABP710	Avsola	Amgen	Approved (2019 FDA)	As per reference agent
STI-002		MabTech/Sorrento Therapeutic
Infliximab biosimilar 1		Nippon Kayaku	Approved (Japan 2014)	As per reference agent

Two more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent [4].

View more information in the IUPHAR Pharmacology Education Project: infliximab

No information available.

No information available.

Summary of Clinical Use
Used in the management of rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease [7] and ulcerative colitis. A subcutaneous formulation is available for use as maintenance option for patients with Crohn's disease/ulcerative colitis following intravenously infliximab therapy.

Summary of Clinical Use

Used in the management of rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease [7] and ulcerative colitis. A subcutaneous formulation is available for use as maintenance option for patients with Crohn's disease/ulcerative colitis following intravenously infliximab therapy.

Mechanism Of Action and Pharmacodynamic Effects
Infliximab binds with high affinity to soluble and transmembrane forms of TNFα thereby inhibiting its binding with its receptors, leading to a decrease in the production of proinflammatory cytokines.

Mechanism Of Action and Pharmacodynamic Effects

Infliximab binds with high affinity to soluble and transmembrane forms of TNFα thereby inhibiting its binding with its receptors, leading to a decrease in the production of proinflammatory cytokines.

External links
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)